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ARTICLE
FMN reduces Amyloid-β toxicity in yeast by
regulating redox status and cellular metabolism
Xin Chen 1,2, Boyang Ji1,2, Xinxin Hao 3, Xiaowei Li1, Frederik Eisele 3, Thomas Nyström 3 &
Dina Petranovic1,2*
Alzheimer’s disease (AD) is defined by progressive neurodegeneration, with oligomerization
and aggregation of amyloid-β peptides (Aβ) playing a pivotal role in its pathogenesis. In
recent years, the yeast Saccharomyces cerevisiae has been successfully used to clarify the roles
of different human proteins involved in neurodegeneration. Here, we report a genome-wide
synthetic genetic interaction array to identify toxicity modifiers of Aβ42, using yeast as the
model organism. We find that FMN1, the gene encoding riboflavin kinase, and its metabolic
product flavin mononucleotide (FMN) reduce Aβ42 toxicity. Classic experimental analyses
combined with RNAseq show the effects of FMN supplementation to include reducing
misfolded protein load, altering cellular metabolism, increasing NADH/(NADH+NAD+) and
NADPH/(NADPH+NADP+) ratios and increasing resistance to oxidative stress. Addition-
ally, FMN supplementation modifies Htt103QP toxicity and α-synuclein toxicity in the
humanized yeast. Our findings offer insights for reducing cytotoxicity of Aβ42, and potentially
other misfolded proteins, via FMN-dependent cellular pathways.
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A lzheimer’s disease (AD) is the most common neurode-generative disorder in aging populations. It is categorizedas a protein misfolding, or protein conformational disease
due to the accumulation of misfolded amyloid-β (Aβ) peptides,
which are defined as one of its principal hallmarks1. The aggre-
gation of Aβ is thought to be an early driver of AD, triggering a
cascade of pathogenic processes, such as inflammation, neurofi-
brillary tau-tangle formation, and synapse dysfunction2. Brain
extracts from AD patients or transgenic mice containing Aβ have
also shown to accelerate cerebral Aβ plaque accumulation and
associated pathology in genetically modified mice3. Aβ42, which
is two amino acids longer than the usual form of the peptide
(Aβ40), is more hydrophobic and prone to form aggregates, being
enriched in patients diagnosed with AD4. Nonetheless, despite
our understanding of AD pathogenesis tremendously advancing
over the past three decades, efforts to translate this knowledge
into effective therapies have, so far, had limited success5.
As a principal organelle responsible for protein quality control
and secretion, the endoplasmic reticulum (ER) is dramatically
perturbed in AD neurons6. Increased Aβ production and/or
aggregation is proposed to result in abnormal levels of ER stress,
contributing towards synapse dysfunction in AD7. To restore cel-
lular proteome homeostasis (proteostasis), ER stress can activate the
unfolded protein response (UPR)8, which in turn promotes the
proper folding of misfolded proteins and suppresses translation,
preventing an overload of the ER with newly synthesized proteins.
As well, UPR leads to an activation of protein degradation via the
ER-associated protein degradation (ERAD) pathway9,10. However,
under chronic or irreversible ER stress conditions, the UPR shifts its
signaling toward cell death11. Modulation of ER-UPR has therefore
been one potential therapeutic strategy for slowing down AD, using
gene therapy or pharmacological approaches12,13.
Due to the strong conservation of protein quality control sys-
tems among eukaryotic cells, the yeast Saccharomyces cerevisiae
has become a powerful model organism to study misfolded
proteins and their implication in human pathologies. Many
available molecular and genetic tools, alongside defined media,
and ease of handling provide many benefits for using this model
system for high-throughput genetic and drug candidate
screenings14,15. Indeed, several humanized yeast models have
been successfully developed to study different aspects of Aβ
toxicity. In humans, Aβ peptides are generated through the
sequential cleavage of the amyloid precursor protein (APP)16 by
BACE and γ-secretase17, which occurs in the secretory pathway
and endocytic pathway in neurons18. In yeast, these human Aβ
peptides can be co-expressed with an ER Kar2 signal peptide, to
ensure that Aβ peptides are transited through the secretory
pathway and exported from the cytoplasm. However, as the yeast
cell wall prevents secreted Aβ from diffusing away extracellularly,
these Aβ peptides re-enter into the cell through endocytosis.
Aβ42 peptides subsequently form more oligomers relative to
Aβ40 and exhibit an increased cellular toxicity in yeast19,20.
To mimic chronic cytotoxicity during AD progression, we
recently developed constitutive Aβ42 and Aβ40 expression
models in yeast21. The constitutive Aβ42 expression provides a
model for moderate and cumulative effects of Aβ42 toxicity, over
a longer period, in conditions of aging yeast cells. Similar to
previous observations in human neurons and other AD model
organisms22, we found that constitutive expression of Aβ42
peptides forms more toxic oligomers and triggers a stronger ER
stress response and UPR, compared to the expression of less toxic
Aβ40 peptides23. We also observed reduced mitochondrial
function and an increase in the production of reactive oxygen
species (ROS), alongside a redirection of energy from cell growth
to maintenance23.
The synthetic genetic array (SGA) approach has been applied
to yeast neurodegeneration models, such as AD, Huntington’s
disease (HD)24 and Parkinson’s disease (PD)25, demonstrating its
robust capability to help identify genes and mechanisms under-
lying phenotypes of interest, such as modeling toxicity of human
disease proteins. In previous studies, the nonessential genome-
wide deletion library has been applied to Aβ42 expression strain
to identify proteins and cellular processes affecting intracellular
Aβ42 aggregation and toxicity26,27. The screening of GFP fused
Aβ42 (Aβ42-GFP) identified four major cellular processes as
being significantly overrepresented: mitochondrial function,
phospholipid metabolism, transcriptional/translational regulation
and inositol biosynthesis26. Another screening of Aβ42 strain
with a α-prepro factor sequence revealed that ER–Golgi traffic,
mitochondrial functioning, cell cycle, DNA replication stress
response and ESCRT machinery play vital roles in Aβ42 toxi-
city27. In both studies, expression of Aβ42 peptides is under the
control of a strong inducible promoter, whereas the Aβ42 pro-
duction in neurons is constitutive. The inducible promoter allows
for well-timed induction of acute cytotoxicity but is accompanied
by a drastic change in carbon-source and metabolism.
Here we take advantage of our improved Aβ42 humanized
yeast model to investigate genetic interactions that can provide
insights into the Aβ42 cytotoxic phenotype. We applied SGA
technology to screen for genetic mutants with an altered
Aβ42 sensitivity profile, by using a yeast deletion mutant library
in which we constitutively expressed Aβ42. The two mutant
libraries comprise a collection of ~4300 deletion strains for
nonessential genes (SGA-V2) and ~1200 temperature sensitive
mutant strains for essential genes (ts-V6). These two sets together
represent more than 80% of all yeast genes28. Compared with
previous studies, inclusion of essential genes screening in our
SGA analysis may further exploit the cellular mechanisms
affecting Aβ42 toxicity. This unbiased yeast genome-scale screen
thus enables a global analysis of synthetic genetic interactions,
which enabled us to identify mechanistic connections between
genes and their corresponding pathways29. Using the tool in this
study, it was therefore possible to map the genome-wide inter-
action networks involved in Aβ42 toxicity. From the essential
mutant library, we identified the riboflavin kinase gene (FMN1)
and its metabolic product flavin mononucleotide (FMN) as being
able to alleviate cellular Aβ42 toxicity.
Results
Yeast genome-wide screening for modulators of Aβ42 toxicity.
Our humanized Aβ42 yeast model was constructed with a cen-
tromeric plasmid under the control of a constitutive GPD pro-
moter, with the Kar2 signal sequence in front of the
Aβ42 sequence21. To minimize the experimental variation during
high-throughput screening, we integrated two copies of the Kar2-
Aβ42-encoding sequence under the control of the GPD promoter
into the SGA starting strain (Y7092) (Supplementary Fig. 1), and
tested it to confirm that the previously characterized phenotypes
were preserved. The main reason for using the Y7092 strain being
that it incorporates reporters and markers necessary for SGA
haploid strain selection, following meiotic recombination. To
create an SGA control query strain, only the promoter and ter-
minator sequences were integrated into the Y7092 strain (Sup-
plementary Fig. 1). The query strains were mated with the yeast
deletion mutant library to generate two arrays, where each dele-
tion strain on the array was combined with either the control or
Aβ42 expression. The scores for growth defects were generated
through comparing the colony sizes of mutants with the Aβ42
expression to mutants with the control (Fig. 1a). Scores < 0 or >0
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represent either a decrease or an increase of growth in mutants
with Aβ42 expression.
The SGA screen was performed independently twice. The
cutoffs for scores were set at ≤−0.2 or ≥ 0.2 (p-adj < 0.05,
Supplementary Fig. 2 and Supplementary Fig. 3). Among
the analyzed 4,300 mutants for nonessential genes, 229 were
scored ≤−0.2, that is these mutants showed higher sensitivity to
Aβ42 toxicity and 259 were scored ≥ 0.2, that is these mutants
showed higher resistance to Aβ42 toxicity, in both SGA tests as
seen through their difference in growth profiles (Fig. 1b and
Supplementary Data 1). The analysis of the 1,200 mutants for
essential genes revealed 198 to have a score ≤−0.2 and 253 had a
score ≥ 0.2 (Fig. 1b and Supplementary Data 2). The gene set
enrichment analysis (GSEA) showed that sensitive mutants
(decreased growth with Aβ42 expression, score ≤−0.2) signifi-
cantly enriched in the vesicle-mediated transport (p= 7.94e-10),
glycosylation (p= 8.01e-5) and response to unfolded protein
(p= 9.63e-6) in nonessential collection (Supplementary Fig. 4).
While in essential collection, the sensitive mutants significantly
enriched in the vesicle-mediated transport (p= 1.55e-8), protein
N-linked glycosylation (p= 4.58e-6) and autophagy (p= 2.52e-4)
(Supplementary Fig. 5). Furthermore, we performed a functional
enrichment analysis via spatial analysis of functional enrichment
(SAFE)30. The enrichment of GO terms suggested that 44% and
34% of the genes mutated in the sensitive mutants in nonessential
and essential collections, respectively, belonged to group 2
(glycosylation, protein folding/targeting, cell wall biosynthesis
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Fig. 1 Genome-wide synthetic genetic array (SGA) screen to identify modulators of Aβ42 toxicity. a A schematic workflow for identifying mutants that
can alter Aβ42 toxicity. b Scores for each genetic mutant, from two independent experiments, with those that significantly change Aβ42 toxicity indicated
in red (p-adj < 0.05, score≥ 0.2), and blue (p-adj < 0.05, score≤−0.2), respectively. c Gene ontology (GO) biological process term distributions among
mutant strains with significantly affected Aβ42 toxicity (p-adj < 0.05, score≥ 0.2 or ≤−0.2). Each number corresponds to a different biological process GO
term as follows: 1. Other; 2. Glycosylation, protein folding/targeting, cell wall biosynthesis; 3. Ribosome biogenesis; 4. Protein degradation; 5. Cytokinesis;
6. Nuclear-cytoplasmic transport; 7. Multivesicular body (MVB) sorting and pH-dependent signaling; 8. mRNA processing; 9. tRNA wobble modification;
10. Peroxisome; 11. Metabolism and fatty acid biosynthesis; 12. DNA replication and repair; 13. Transcription and chromatin organization; 14. Vesicle traffic;
15. Cell polarity and morphogenesis; 16. Mitosis and chromosome segregation; 17. rRNA and ncRNA processing; 18. Respiration, oxidative phosphorylation,
mitochondrial targeting. The top 3 GO terms are indicated as number in each individual category. d Spatial analysis of functional enrichment of mutants
with significantly (p-adj < 0.05) affected Aβ42 toxicity and score≥ 0.2 or ≤−0.2. Blue colored points indicate mutants more sensitive to Aβ42 toxicity
(score≤−0.2) and yellow color indicates mutants that are more resistant (score≥ 0.2), as measured via their growth during SGA screening. GO biological
process terms are indicated as in c and outlined by dashed lines.
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the genes mutated in the sensitive mutants in nonessential and
essential collections, respectively, were represented by group 14
(vesicle traffic processes) (enrichment p value < 0.05, Fig. 1c, d).
Moreover, the enrichment of GO terms for resistant mutants that
had increased growth with Aβ42 expression (score ≥ 0.2) was
represented in different biological processes in both mutant
collections (Fig. 1c, d). Besides these results, among the essential
genes required for Aβ42 tolerance, many belonged to group 4
(protein degradation processes) as well as group 15 (cell polarity
and morphogenesis processes). Essential genes, which mutations
caused increased resistance against Aβ42, were enriched in group
13 (transcription and chromatin organization processes), group
16 (mitosis and chromosome segregation processes) and group 17
(rRNA and ncRNA processing processes) (enrichment p value <
0.05, Fig. 1c, d). The complete list of GO terms from SAFE
analysis can be found in Supplementary Tables 1 and 2.
Yeast mutants with increased sensitivity to Aβ42 toxicity. Gene
set enrichment analysis revealed that Aβ42 toxicity was found to
be increased in mutants involved in protein secretion and
degradation processes, including protein translocation, post-
translational modifications, folding to a mature protein, ER to
Golgi transport, ER to vacuole transport, ERAD and autophagy.
To visualize the functions of these mutated genes, we mapped
all mutants that met our significance and growth score cut offs
(p-adj < 0.05, score ≤−0.2 or ≥0.2) on a schematic representation
of protein secretion and degradation pathways map (Fig. 2a).
These findings are in accordance with our previous findings from
genome-wide transcriptional analysis, which showed that Aβ42
expression triggers a strong ER stress, resulting in activation of
the UPR to upregulate processes involved in protein folding/
maturation, ER-to-Golgi trafficking and ERAD23 (Supplementary
Fig. 6).
By selecting more stringent cutoff values (p-adj < 0.05, score ≤
−0.5 or ≥0.5), 47 sensitive mutants and 7 resistant mutants were
identified (listed in Supplementary Tables 3 and 4, respectively).
Interestingly, 35 out of these 54 mutants were determined in human
(HomoloGene, https://www.ncbi.nlm.nih.gov/homologene). To
assess the potential clinical relevance of these genes, we further
examined the mRNA expression of the corresponding human
orthologs in the prefrontal cortex of AD patients versus controls
(healthy) samples, which enabled us to examine 28/35 human
ortholog genes. We discovered that 14 and 8 out of the 28 human
orthologs showed significantly decreased and increased mRNA
levels, respectively (Fig. 2b and Supplementary Fig. 7). We further
manually tested the phenotypes of the 28 corresponding yeast
mutants, of which 13 mutant phenotypes were confirmed by
random spore test (Table 1).
Six out of these 13 mutants had functions related to ER and
glycosylphosphatidylinositol (GPI) biosynthesis (FMN1, YIP1,
CNE1, ERG27, GPI13, and GPI1), four were related to glycosyla-
tion and translocation (WBP1, OST1, OST3, SEC63), and three
were functionally associated with COPI transport (SEC21, ERD2,
RER1). Interestingly, of these human orthologs, four (SEC6331,
KDELR132, RER133, and RPN134), which are the orthologs of
yeast SEC63, ERD2, RER1, and OST1, respectively, have already
been identified in previous studies for association with AD31–34.
Defects in riboflavin metabolism increases Aβ42 toxicity.
Among these confirmed mutants with human orthologs, we
found the FMN1 gene. FMN1 encodes an essential enzyme that is
responsible for catalyzing the phosphorylation of riboflavin
(vitamin B2), in turn to produce the active forms of this vita-
min35. Riboflavin has been found to act as a potential neuro-
protective agent, preventing and/or modifying the process of
neurological disorders by improving conditions of oxidative
stress, mitochondrial dysfunction, and neuroinflammation36.
Moreover, mRNA levels of human RFK (riboflavin kinase), the
ortholog of yeast FMN1, have found to be significantly lower in
the cerebellum, visual cortex and prefrontal cortex of AD patients
versus controls (Fig. 2c).
Riboflavin biosynthesis in S. cerevisiae utilizes ribulose
5-phosphate and guanosine-5′-triphosphate (GTP) as precursors
and proceeds through pyrimidine intermediates37. The active
forms of riboflavin, FMN and flavin adenine dinucleotide (FAD),
are formed in two consecutive reactions which are catalyzed by
FMN1 and FAD1 (FAD synthetase), respectively (Fig. 3a). The
SGA screening showed that the fmn1 mutant was sensitive to
Aβ42 toxicity with a score of −0.55 and −0.66 from the two
independent SGA screens. Moreover, complementation assays
confirmed that fmn1 mutant was crucial for Aβ42 toxicity. As
well, increased Aβ42 toxicity in the fmn1 mutant background
could be reduced by expression of FMN1 or the human ortholog
RFK (Fig. 3b and Supplementary Fig. 8). We further measured the
dynamic transcript levels of FMN1 in both Aβ42 and control
strains. The results showed that FMN1 mRNA levels were
significantly increased in the post-diauxic shift (PD) and
stationary phases (SP) cells compared to exponentially growing
cells (EX) in both Aβ42 and control strains (p-adj < 0.05, Fig. 3c).
In the Aβ42 strain, there was 4.10, 2.55, 2.25-fold increase in PD,
day 2, and day 3 compared to EX, respectively. In the control
strain, there was 4.4, 2.9, and 2.4-fold increase in PD, day 2, and
day 3 compared to EX, respectively (Fig. 3c).
FMN supplementation reduces Aβ42 toxicity. To test whether
the increased Aβ42 toxicity was due to the fmn1 mutation or to a
lack of downstream metabolic products, we cultivated the
Aβ42 strain with fmn1 mutation in culture medium containing
either 5 mM FMN or 5 mM FAD, a metabolic product that is
one-step down from FMN in the riboflavin biosynthetic pathway.
Here, the Aβ42 toxicity was only found to be reduced by sup-
plementation with 5 mM FMN, not FAD (Fig. 3d). As well,
supplementation with FMN could also rescue the growth
impairment of the control strain with fmn1 mutation (Supple-
mentary Fig. 9). As a riboflavin-nucleotide coenzyme, FMN is
essential for redox reactions and participates in a wide range of
biological processes, including carbohydrate, fatty acid and amino
acid metabolisms38. These observations suggest that maintaining
a sufficient level of FMN may be required for both Aβ42 and
control strains during different stages of cell growth. Further-
more, these results also suggest FMN deficiency could contribute
towards Aβ42-triggered toxicity. To test this, we evaluated cellular
viability in the presence of different concentrations of FMN in the
culture medium following chronological aging. The significantly
increased viability of Aβ42 strain was FMN-dosage dependent
(Fig. 3e, f). The fractions of non-viable cells on day 5 were 61% in
Aβ42 strain without FMN, comparing to 45%, 39.4%, 35%, and
33.3% with 1, 3, 5, and 7 mM FMN added, respectively (Sup-
plementary Fig. 10). Moreover, supplementation of FMN also
improved viability in the control strain as well (p-adj < 0.05,
Supplementary Fig. 11).
FMN supplementation plays important roles in protein fold-
ing. Increasing evidence indicates that Aβ42 peptides are prone to
form aggregates, which contributes notably to the neurotoxicity
that occurs in AD pathogenesis39. To monitor whether the fmn1
mutation contributed to protein aggregation, we used GFP-tagged
Hsp104 (heat shock protein 104) as a reporter for protein
aggregation. In S. cerevisiae, Hsp104 plays a crucial role in ther-
motolerance, binding to aggregated proteins after exposure to
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heat shock40. The GFP-tagged Hsp104 can therefore be observed
as intracellular foci and inclusions using fluorescence micro-
scopy41. Cells from both the fmn1 mutant and the wild type were
subjected to heat shock at 38 °C for 90 min to induce protein
misfolding and aggregation. Here, fmn1 mutant was found to
contain significantly (p < 0.001) more cells in the class 3 category
(55.5 ± 4.6%, ≥3 aggregates/cell), than in the wild type strain
(10.4 ± 5.7%, Fig. 4a). This indicates that FMN1 could be involved
in sequestering small aggregates/oligomers into larger inclusion
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Fig. 2 Roles of protein secretion and degradation processes in Aβ42 toxicity. a Mutants with significantly changed Aβ42 toxicity mapped to protein
secretory and degradation processes (p-adj < 0.05 and score≥ 0.2 or ≤−0.2). b The mRNA expression levels of 28 human orthologs in the prefrontal
cortex of Alzheimer’s disease (AD) patients versus normal controls. Genes were ranked according to the size of their significant difference between the
two groups. Out of the 28 human orthologs, 22 (79%) showed significantly changed mRNA levels (p-adj < 0.05). c Comparison of human RFK (ortholog of
yeast FMN1) mRNA levels in three different brain regions (cerebellum, prefrontal cortex and visual cortex) between AD patients and normal controls.
Asterisks (*) indicate significant differences (p-adj < 0.0001).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14525-4 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:867 | https://doi.org/10.1038/s41467-020-14525-4 | www.nature.com/naturecommunications 5
proteotoxicity42. Correspondingly, we observed that 5 mM FMN
supplementation decreased 21% of aggregate formation in
Aβ42 strain, which links to Aβ42 induced toxicity (Fig. 4b).
To further investigate if FMN supplementation can help cells
to cope with a protein misfolding burden, we again stressed the
cells, but this time directly targeted proteins as opposed to using
general stress conditions. To achieve this, we used L-azetidine-2-
carboxylic acid (AZE), an analog of L-proline which causes
protein misfolding. In the control strain, we observed that cellular
viability was significantly (p < 0.05) decreased with 5 mM and
10 mM AZE treatment, but cells with 5 mM FMN supplementa-
tion showed improved survival than without supplementation
(Fig. 4c). Here, the number of viable cells was measured by colony
forming units (CFU), which showed significantly (p < 0.05)
higher viability in FMN supplemented cultures with either 5 or
10 mM AZE treatment compared to cultures without FMN
(Fig. 4d). This result indicates that FMN supplementation could
increase cellular capacity to cope with misfolded protein stress.
FMN improves redox homeostasis in Aβ42 strain. Oxidative
stress has been implicated in many disease processes including
neurodegenerative disorders and aging43. A balanced ratio of
cellular oxidants and antioxidants is important to maintain a
state of redox homeostasis, which is mainly determined by the
ratios between reduced and oxidized forms of redox cofactors,
particularly nicotinamide adenine dinucleotide phosphate
(NADP) and nicotinamide adenine dinucleotide (NAD). In the
Aβ42 strain, 5 mM FMN supplementation resulted in a sig-
nificant (p < 0.05) increase of the NADPH/(NADPH+NADP+)
ratio during EX and PD conditions (Fig. 5a and Supplementary
Fig. 12). Under these conditions, NADH/(NADH+NAD+)
ratios were also significantly (p < 0.05) improved as well (Fig. 5b
and Supplementary Fig. 12). Finally, FMN supplementation was
also found to increase the NADPH/(NADPH+NADP+) ratio in
the control strain without Aβ42 expression (p < 0.05, Supple-
mentary Figs. 12 and 13a). As oxidative stress has been implicated
as one of causative factors for aging44, the improved reducing
environment might contribute to the increased viability in the
control strain during chronological aging (Supplementary
Fig. 11). Therefore, as well as lessening the propensity for protein
misfolding, FMN supplementation may also alleviate Aβ42 toxi-
city through improving redox homeostasis which can help overall
cell response to oxidative stress.
To investigate this, we challenged the Aβ42 strain with the
endogenous oxidant hydrogen peroxide (H2O2). Here, cells were
grown to mid exponential phase and exposed to incremental
levels of H2O2. The length of the lag phase was calculated from
exponential growth curves, by calculating the time after cells were
arrested in growth following H2O2 treatment to the point where
they returned to maximum growth rate45. We observed that Aβ42
cells displayed prolonged lag phases with higher H2O2 concen-
trations. However, the supplementation of 5 mM FMN signifi-
cantly (p < 0.05) shortened the extended lag phases (Fig. 5c, d).
An oxidative stress tolerance assay for the control strain was also
performed using spot tests with medium containing different
concentrations of H2O2. As seen with the liquid growth assay,
cells with 5 mM FMN supplementation demonstrated a higher
H2O2 tolerance than without supplementation (Supplementary
Fig. 13b). Taken together, these results indicate that FMN
supplementation can be beneficial for oxidative stress tolerance,
in both Aβ42 and control strains.
FMN supplementation causes a global transcriptional response.
To gain further insight into the mechanism behind how FMN
supplementation helps to improve cell physiology, Aβ42 and
control strains with and without 5 mM FMN supplementation
were sampled for RNA sequencing (Supplementary Fig. 12).
Principal component analysis (PCA) showed that the Aβ42 strain
with FMN supplementation had a distinct gene expression profile
(Supplementary Fig. 14a). Differential gene expression analysis
identified more than a third of the genome (n= 2081 genes) to be
significantly (p-adj < 0.05) up or downregulated in the Aβ42 strain
upon FMN supplementation (hereafter referred to as FMN_Aβ42,
Supplementary Data 3), compared to 389 genes in the control
strain (hereafter referred to as FMN_control, Supplementary
Fig. 14b and Supplementary Data 4). We next performed gene set
analysis (GSA) on the significantly changed genes (p-adj < 0.05),
wherein 53 and 22 gene sets were found to be significantly enri-
ched in the FMN_Aβ42 and FMN_control strain respectively
(p-adj < 0.05, Supplementary Fig. 15). Thirty genes were sig-
nificantly differentially expressed in both FMN_Aβ42 and
FMN_control (p-adj < 0.05, log2 Fold change ≤−1 or ≥ 1), with 17
and 8, respectively, out of these 30 genes being related to meta-
bolic process and ion transport (Supplementary Fig. 16). This is
consistent with the expected role of FMN as a cofactor for fla-
voproteins, participating in carbohydrate, amino acid, fatty acid
and ion metabolic pathways46.
Gene set enrichment analysis also revealed that for the
Aβ42 strain with FMN supplementation, pathways that were
upregulated were mainly involved in carbohydrate metabolism,
Table 1 Modifiers of Aβ42 toxicity in protein secretion and degradation processesa.
Systematic name Standard name Cellular function Human ortholog
YAL058W CNE1 Folding and quality control of glycoproteins CANX/CLGN
YOR085W OST3 Oligosaccharyltransferase TUSC3
YDR236C FMN1 FMN biosynthesis RFK
YEL002C WBP1 N-linked glycosylation of proteins in the ER DDOST
YOR254C SEC63 Target and import proteins into ER SEC63
YBL040C ERD2 Maintenance of normal levels of ER-resident proteins KDELR1/KDELR2/KEDLR3
YGR172C YIP1 Biogenesis of ER-derived COPII transport vesicles YIPF4/YIPF5/YIPF7
YNL287W SEC21 ER to Golgi transport of selective cargo COPG2
YLR100W ERG27 Ergosterol biosynthesis HSD17B7
YCL001W RER1 Retention of membrane proteins to ER RER1
YGR216C GPI1 Synthesis of GlcNAc-PI PIGQ
YLL031C GPI13 ER membrane localized phosphoryltransferase PIGO
YJL002C OST1 Oligosaccharyltransferase RPN1
aYeast genes with human orthologs were identified in SGA screening and confirmed by random spore test.
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glycogen biosynthesis, ion transport and homeostasis, ATP biosynth-
esis, mitochondrial translation, and cellular response to oxidative
stress. In contrast, gene sets related to ribosome function, cytoplasmic
translation, and cellular amino acid biosynthesis were all down-
regulated in the Aβ42 strain with FMN supplementation (p-adj <
0.05, Fig. 6a and Supplementary Fig. 15a). Many genes involved in
amino acid biosynthesis were also significantly downregulated in the
Aβ42 strain with FMN supplementation (p-adj < 0.05, Supplemen-
tary Fig. 17). From these results one could speculate that FMN can
improve protein homeostasis under stress by mediating the
repression of amino acid biosynthesis and protein synthesis. This
would enable a reduction in ER stress by reducing the load of newly
synthesized proteins.
FMN supplementation significantly increased redox cofactors
(Fig. 5a, b), that are mainly generated in carbohydrate
metabolism47, so we further investigated the differentially
expressed genes in central carbon metabolism (Fig. 6b). HXT148
and HXT349, encoding low affinity glucose transporters, showed
to be downregulated in the Aβ42 strain with FMN supplementa-
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Fig. 3 Riboflavin kinase and its metabolic product FMN reduce Aβ42 toxicity. a Schematic illustration of the riboflavin biosynthesis metabolic pathway.
FMN, flavin mononucleotide; FAD, flavin adenine dinucleotide. b Complementation assays to confirm fmn1 mutant is causal towards increasing
Aβ42 sensitivity. Vector: MoBY empty plasmid; ScFMN1: pFMN1-MoBY plasmid; HsRFK: P416 GPD-human RFK plasmid. c FMN1 mRNA expression during
exponential growth (EX), post-diauxic shift phase (PD) and stationary phase (day 2 and day 3). Results from qPCR are normalized to EX of each strain and
shown as the average values ± SD from three independent biological replicates. Asterisks (*) indicate significant differences compared to EX in both Aβ42
(red) and control (blue) strains (p < 0.05). d Ten-fold serial dilutions of the Aβ42 expression strain with fmn1 mutation carrying the aforementioned
plasmids with supplementation of 5 mM FAD or 5mM FMN in the medium. e Survival of the Aβ42 strain during stationary phase with different
concentrations of FMN supplemented. Viability is shown as the fraction of propidium iodide (PI) negative cells (n= 3 ± SD). f Flow cytometry and
fluorescence micrographs of PI staining in the Aβ42 strain after 5 days of cultivation. Cells that are stained red represent nonviable cells. Scale= 10 µm.
Source data are provided as a Source Data file.
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Fig. 4 FMN supplementation facilitates protein folding. a Quantification of aggregate foci after heat shock for 90min in wild type and fmn1 mutant yeast
cells. Class1: one aggregate per cell (as highlighted by single GFP cluster); Class 2: two aggregates per cell; Class 3: ≥3 aggregates per cell. Bar graphs show
fractions of Class 1, 2, and 3 cells for each strain. Above 500 cells were measured per sample with results shown as average values ± SD from six biological
experiments. Scale= 2 µm. **p < 0.001. b Western blot of Aβ42 expression from stationary phase cultures, using the 6E10 Aβ specific antibody. GAPDH
was used as the loading control. c Ten-fold serial dilutions of the control strain after 3 h of treatment with 5 or 10 mM L-azetidine-2-carboxylic acid (AZE).
d Colony forming unit (CFU) measurement of control strain after 5 mM or 10mM of AZE treatment as a measurement of viability (n= 3 ± SD). *p < 0.05.
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Fig. 5 FMN supplementation increases cellular tolerance to oxidative stress in Aβ42 strain. a Ratio of NADPH/(NADPH+NADP+) in the Aβ42 strain
without or with FMN supplementation during EX and PD growth phases respectively (n= 4 ± SD; *P < 0.01). b Ratio of NADH/(NADH+NAD+) in the
Aβ42 strain without or with FMN supplementation during EX and PD growth phases (n= 4 ± SD; *P < 0.01). c, d Aβ42 cells display an increased H2O2
tolerance when supplemented with FMN. Aβ42 cells without or with FMN supplement were grown to mid exponential phase (OD≈ 0.5–0.6) and treated
with different concentrations of H2O2. Cell growth was monitored using a microplate reader (c) with lag phase time analyzed using the R package
growthrates (d). The lag phase indicates the time from H2O2 treatment until maximum growth rate, determined by the exponential growth phase. Results
shown are average values ± SD of biological duplicates. The asterisk (*) indicates significant difference (p < 0.05). Source data are provided as a Source
Data file.
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transporters (HXT2, HXT4, HXT6, and HXT7), and hexose
transporters (HXT8, HXT10, HXT13, and HXT17) were upregu-
lated. Most genes (20/22) in the tricarboxylic acid (TCA) cycle
were also upregulated after FMN supplementation as well
(Fig. 6b). The TCA cycle generates NADH and FADH2, which
in turn act as electron donors for oxidative phosphorylation in
the electron transport chain. Meanwhile, we found that genes
encoding respiratory complexes in the electron transport chain
showed significantly (p < 0.05) increased transcription after FMN
supplementation (Fig. 6c). Iron transport plays a vital role in
living organisms by participating in a variety of electron transfer
reactions and enzymatic reactions. Here, genes involved in iron
transport and homeostasis were also mostly upregulated after
FMN supplementation (Supplementary Fig. 18). In terms of what
decreased in expression after FMN supplementation, genes
involved in ergosterol and fatty acid synthesis, the second branch
of pyruvate metabolism, were mainly downregulated, along with a
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Fig. 6 Transcriptional responses in Aβ42 strain with FMN supplementation. a Gene set enrichment analysis. Fold enrichment indicates the magnitude of
enrichment in our dataset against the S288C yeast genome background using DAVID bioinformatics resources. b Fold changes in the expression of genes
which encode central metabolic pathways. c Fold changes in expression of genes coding for mitochondrial electron transport chain proteins. All comparison
is between FMN supplementation, and without (p-adj < 0.05 according to Benjamini–Hochberg method).
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consistent with the increased NADPH/(NADPH+NADP+)
ratio we found in the FMN supplemented strains (Fig. 5a). The
synthesis pathways for the storage carbohydrates glycogen and
trehalose were also enriched with upregulated genes after FMN
supplementation (Fig. 6b). The upregulated genes in trehalose
synthesis may therefore link the stress resistant phenotype of
FMN supplemented cells to the alternative role of trehalose as a
stress protectant. Indeed, it has been reported previously that
trehalose can stabilize the structures and enzymatic activities of
proteins against thermal denaturation50, and can prevent the
formation of Aβ aggregates and reduce its cytotoxicity51.
Our previous observations showed that Aβ42 expression
induces strong ER stress and activates the UPR as a means of
the cell attempting to reduce the misfolded protein burden
generated by Aβ4223. After FMN supplementation of the
Aβ42 strain, genes related to the oxidative stress response,
protein degradation, and endocytosis were found to be sig-
nificantly (p < 0.05) upregulated (Supplementary Fig. 19), sug-
gesting cells are restoring ER homeostasis. These findings are
consistent with western blot analysis showing that FMN
supplementation decreased levels of Aβ42 aggregates (Fig. 4b).
Overexpression of flavoprotein Dus2p reduces Aβ42 toxicity.
FMN participates in many biological processes, as can be seen
through our transcriptional analysis following FMN supple-
mentation. This could principally be due to its role as an essential
cofactor for a variety of FMN-dependent enzymes. To investigate
the potential roles of flavoenzymes in general in Aβ42 toxicity,
11 strains with single flavoenzyme gene deletions were assessed.
These flavoenzymes are involved in myriad roles, from reactions
involving electron transfer in the mitochondria (Cyb2p, Glt1p,
Pst2p), redox processes in the cytoplasm (Lot6p, Oye2p, Rfs1p),
tRNA-modification (Dus2p, Dus3p, Dus4p), to central metabolic
functions (Met5p, Aro2p)52. First, the 11 single deletion strains
were transformed with a plasmid for constitutive expression of
Aβ42. Thereafter, cellular viability during chronological aging was
tested with 5 mM FMN supplementation. As found previously
(Fig. 3e), we observed that FMN significantly increased
Aβ42 survival. As in several strains, despite flavoenzyme genes
being deleted, FMN supplementation was still found to sig-
nificantly increase Aβ42 viability in the mutant strains: rfs1Δ,
pst2Δ, lot6Δ, oye2Δ, aro2Δ, dus3Δ and dus2Δ (p < 0.05). FMN
supplementation however did not affect Aβ42 viability in dus4Δ,
cyb2Δ and glt1Δ mutant strains (p > 0.05). Finally, in contrast,
FMN supplementation significantly decreased Aβ42 viability in
the met5Δ mutant strain (p < 0.05, Supplementary Fig. 20a).
Since cyb2Δ, glt1Δ, and met5Δ significantly altered the
beneficial effects of FMN supplementation in the Aβ42 strain,
we tested to see if the opposite would be true if Aβ42 toxicity
could be alleviated by overexpression of these genes. Except for
cyb2, glt1 and met5 genes, dus2 gene was also tested due to dus2Δ
significantly decreased Aβ42 viability (p < 0.05, 9.2 ± 0.9% of live
cells in dus2Δ strain vs 89.3 ± 0.9% of the control Aβ42 strain).
Only DUS2 overexpression significantly increased viability in
Aβ42 strain, showing 71.4 ± 4.5% and 44.3 ± 5.2% of live cells, in
1- and 4-day-old stationary phase cultures respectively, compared
to 60.8 ± 5.5% and 31.1 ± 3.4% of the control Aβ42 strain (p <
0.05, Supplementary Fig. 20b). This would therefore suggest that
DUS2 could be involved in modulating Aβ42 toxicity. The mRNA
expression levels of human ortholog DUS2 were also significantly
lower in cerebellum, visual cortex and prefrontal cortex of AD
patients, compared to controls (Supplementary Fig. 21). More-
over it has been reported that Dus2 serves as an inhibitor in the
regulation of PKR function53, an interferon-induced protein
kinase. As the activation of PKR is known to be related to ER
stress-induced apoptosis in AD54, DUS2 could be investigated as
an additional gene target alongside FMN1 for reducing Aβ42
toxicity.
FMN reduces HTT103QP and α-synuclein toxicity. Many
neurodegenerative disorders share a common hallmark of aber-
rant protein aggregation. To test the specificity of FMN effects,
we assessed its effect on two other proteins: HTT103QP and
α-synuclein, using humanized yeast models.
HD develops when the CAG trinucleotide repeats cause the
polyglutamine (polyQ) expansion in the Huntingtin (HTT)
gene55. In yeast, repeat lengths of 47 or more lead to HTT
protein aggregation and the formation of typical inclusion bodies
that are similar to those of HD patients56. The HTT103QP model
was reconstructed with 103 glutamines expansion under the
control of constitutive GPD promoter. We then evaluated cellular
viability in the presence of 5 mM FMN following chronological
aging. The fractions of viable cells were significantly higher until
day 11 in the HTT103QP strain with FMN supplementation,
compared to without supplementation (Fig. 7a). In previous
experiments, we observed that FMN supplementation was
beneficial for oxidative stress tolerance in Aβ42 strain. Since
increased oxidative stress has long been held as a key player in the
HD pathogenesis57, we further investigated if FMN supplementa-
tion could protect HTT103QP cells from oxidative stress, as was
the case in Aβ42 strain. The results showed that HTT103QP cells
had prolonged lag phases during H2O2 stress, and the FMN
supplementation could significantly shorten the extended lag
phases (p < 0.05, Fig. 7c and Supplementary Fig. 22a).
The pathological hallmark of PD is the accumulation of high
levels of oxidative free radicals and the presence of cytoplasmic
inclusions called Lewy bodies, which predominantly composed of
the misfolded and aggregated α-synuclein58. In the humanized
PD yeast model, the expression of α-synuclein was controlled
under the inducible MET25 promoter, which is induced by
depletion of methionine from the culture medium59. We
observed that supplementation of FMN improved cellular
viability in the α-synuclein strain as well (p < 0.05, Fig. 7b). The
oxidative stress tolerance assay was also performed, which
showed cells with FMN supplementation had a higher H2O2
tolerance than cultures without supplementation (p < 0.05, Fig. 7d
and Supplementary Fig. 22b). These results indicate that FMN
supplementation could offer increased oxidative stress tolerance
in different neurodegenerative disease models.
Discussion
In this study, we used genome-wide SGA screening to identify
modulators of Aβ42 cytotoxicity. From nearly 5,500 mutants we
identified a subset with increased sensitivity towards Aβ42, which
were significantly enriched in protein secretion and degradation
processes, as well as to cytoprotective mechanisms for main-
taining cellular proteostasis. Moreover, we specifically identified
riboflavin kinase (FMN1 gene), and its metabolic product FMN,
as critical modulators of Aβ42 toxicity. Transcription of RFK, the
human orthologue of FMN1, was also found to be significantly
decreased in brain tissues of AD patients (Fig. 2c), thereby sug-
gesting a conserved evolutionary function of riboflavin kinase in
underlying processes that govern proteostasis management
in cells.
Brain cells are particularly susceptible to oxidative stress due to
their higher metabolic activity and lower antioxidant activity,
compared to many cells of other organs, suggesting that redox
metabolism may be an important factor for neuronal death. There
are several plausible models proposing how riboflavin could
protect cells against oxidative stress by: (1) enhancing the
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glutathione redox cycle60, (2) deactivating the lipid peroxides61,
(3) direct activity against free radicals62, and (4) enhancing
antioxidant enzyme activities63. Oxidative stress is also
often accompanied by mitochondrial dysfunction, which may
exacerbate disease progression64 and it was shown in several case
studies that riboflavin administration in patients with mito-
chondrial diseases can lead to clinical improvement65,66.
The crucial roles of riboflavin are linked to its active forms
FMN and FAD. With a tricyclic heteroaromatic isoalloxazine
ring, FMN and FAD can reversibly accept and donate one or two
electrons, with the majority of flavoenzymes catalyzing reduction-
oxidation reactions in metabolic pathways. Transcriptomics
analysis of our yeast AD model showed that the genes involved in
TCA cycle and oxidative phosphorylation processes were sig-
nificantly upregulated by FMN supplementation (Fig. 6), sug-
gesting that FMN mediates an increase in the generation of ATP
and NADH. In addition, we also observed significantly down-
regulated expression of genes related to ergosterol and fatty acid
synthesis pathways, indicating possible increase in the release of
reduced NADPH (Fig. 6).
Declining mitochondrial function is known to lead to abnor-
mal energy metabolism, which plays an important role in med-
iating AD dysfunction and degeneration67,68. Mitochondrial
dysfunction also often accompanies elevated ROS production,
leading to oxidative stress that may exacerbate AD progression
through oxidative damage to cellular structures, proteins, lipids
and DNA64. In our previous report, aberrant fragmented mito-
chondrial structures and increased ROS levels in our Aβ42 model
were indeed observed23. The redox couples NAD(P)H/NAD(P)+
are the major electron transfer carriers for reduction-oxidation in
cells, and thus vital for diverse biochemical processes. During
aging, decreased NAD(P)H and redox ratios could contribute to
AD progression, which may be due to a decline in TCA cycle
enzymes activites69. Studies in aging and AD-like neurons from
nontransgenic and 3 × Tg-AD mice showed that adding an NAD
(H) precursor, in order to stimulate a balanced redox defense is
neuroprotective70. In accordance with previous findings, we
observed significantly increased NADPH/(NADPH+NADP+)
and NADH/(NADH+NAD+) ratios and cellular tolerance to
oxidative stress in our Aβ42 strain when supplemented with FMN
(Fig. 5), which may partially contribute to the increased viability
during chronological aging (Fig. 3e, f and Supplementary Fig. 11).
Targeting redox metabolism and FMN cofactors may thereof be
an effective therapy for combating oxidative stress in aging
and AD.
Another important group of flavoenzymes are involved in
reactions related to tRNA-modifications. In particular, the Dus1-4
family of FMN-dependent flavoenzymes, encode tRNA-
dihydrouridine synthases, which reduce uracil to dihydrouridine
at specific positions on tRNA. Moreover, this is one of the most
common modifications of nucleosides in tRNA in all living
cells71. So far, only one dihydrouridine synthase in human has
been identified, which is an ortholog of the yeast Dus2p72. The
human Dus2p has also been found to be upregulated in pul-
monary carcinogenesis patients, resulting in higher levels of
dihydrouridine modification73. In our Aβ42 strain, dus2Δ sig-
nificantly decreased cellular viability (Supplementary Fig. 20a),
whilst DUS2 overexpression significantly increased viability,
suggesting that Dus2p might be a direct contributing factor
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Fig. 7 FMN supplementation reduces HTT103QP and α-synuclein toxicity. Viability of the HTT103QP strain (a) and the α-synuclein strain (b) with 5mM
FMN supplemented during chronological aging. Viability is shown as the fraction of PI negative cells (n= 3 ± SD). HTT103QP cells (c) and α-synuclein cells
(d) display an increased H2O2 tolerance with FMN supplementation. Cells without or with FMN supplement were grown to OD≈ 0.2 and treated with
different concentrations of H2O2. Cell growth was monitored using a microplate reader with lag phase time analyzed using the R package growthrates.
Results shown are average values ± SD of biological duplicates. The asterisk (*) indicates significant difference (p < 0.05). Source data are provided as a
Source Data file.
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investigation on the biological significance of Dus2 could improve
our understanding of this flavoprotein in AD pathogenesis as well
as help determine its potential as a therapeutic target against the
disease.
With respect to the fmn1 mutant identified from SGA screen-
ing, the lack of the functional enzyme resulted in the formation of
multiple amorphous-like aggregates, rather than one or two large
inclusions (Fig. 4a). Previous work has found these amorphous
aggregates to be severely toxic to yeast cells74, however, supple-
mentation of FMN, the product of FMN1 activity, helped alleviate
misfolded protein stress in control strain (Fig. 4c, d).
In AD, ER stress plays one of the principle roles in determining
disease pathogenesis, as it leads to activation of the UPR, which
aims to restore ER homeostasis. Previous findings show that UPR
signaling can be modulated through finetuning the expression of
various gene targets, depending on the nature of the stress75. In
our previous study we found that Aβ40 triggers a mild stress
response, whilst Aβ42 triggers a significantly stronger stress
response, alongside a stronger UPR response, affecting many
aspects of cell physiology23. Considering the global effects of
Aβ42, we used genome-wide transcriptional analysis to under-
stand how Aβ42 toxicity is alleviated by FMN supplementation.
FMN showed to enhance the efficacy of UPR in the Aβ42 strain
by downregulating amino acid synthesis and upregulating protein
degradation (Supplementary Fig. 17 and 19). This may also
explain our findings that Aβ42 aggregates in our Aβ42 strain were
reduced following supplementation with FMN (Fig. 4b).
In the ER, the relative higher concentration of oxidized glu-
tathione (GSSG) is essential for the formation of native disulphide
bonds in nascent proteins76. Reduced glutathione (GSH) also
contributes towards robust cell function by acting as an endo-
genous antioxidant and deactivating ROS. To control ER redox
homeostasis during protein folding, oxidized GSSG should
therefore be reduced to GSH through glutathione reductase,
which requires FAD that is produced from FMN, as a coen-
zyme77. The connection between the glutathione cycle and its
dependency on flavins in the ER, may therefore also contribute to
the beneficial effects of FMN supplementation.
Genome-wide screenings have been performed in yeast models
with a mutant HTT fragment or α-synuclein, which showed the
toxicity medicated by these two proteins was regulated by dif-
ferent sets of conserved genes and pathways78. Genes that modify
the mutant HTT fragment cluster in the cellular processes related
to stress response, protein folding, and ubiquitin-dependent
protein catabolism, whereas genes in the functional categories of
lipid metabolism and vesicle-mediated transport processes are
isolated in the α-synuclein screen78. A yeast genome-wide screen
based on high content microscopy (HCM) found that huntingtin
exon 1 (Httex1)-103Q expression showed the ribosome quality
control (RQC) machinery as playing a key role in regulating the
nuclear localization and adverse effects of Httex1-103Q pro-
teins79. Although various biological processes were involved in
AD, HD and PD, the oxidative stress is critical to neuronal death
in neurological disorders80. Neurons are particularly vulnerable
to oxidative damage due to their high oxygen consumption (20%
of total consumption), abundance of peroxidation-susceptible
lipid bilayer and weak antioxidant defense80. The beneficial
effects of FMN for oxidative stress tolerance in AD, PD and HD
yeast models showed potential to further explore the effectiveness
in attenuating neurodegenerative pathology.
In summary, our Aβ yeast model provides a useful tool for
identifying genetic modifiers of Aβ cytotoxicity and investigating
their mechanisms of action. Furthermore, this study provides
highly informative data regarding the beneficial effects of FMN
supplementation on cellular metabolic activity, redox homeostasis
and proteostasis in the Aβ42 strain. Due to a strong correlation
between oxidative stress, metabolic syndrome and AD81, under-
standing how FMN and flavoenzymes attenuate Aβ-induced
cytotoxicity could be highly beneficial for clarifying molecular
mechanisms in AD onset and progression.
Methods
Plasmids and strains. All plasmids and yeast strains used in this study are spe-
cified in Supplementary Tables 5 and Table 6, respectively. The primers used in this
study are listed in Supplementary Table 7. E. coli DH5α was used for plasmid
amplification. Plasmids for gene overexpression were constructed by Gibson
assembly of the gene fragments, which were amplified from CEN.PK 113-11C
genomic DNA, with a p416 GPD vector backbone, resulting in plasmids p416
GPD-FMN1, p416 GPD-CYB2, p416 GPD-GLT1, p416 GPD-MET5 and p416
GPD-DUS2, respectively. Codon optimized human RFK gene was synthesized and
digested with restriction enzymes and ligated into the p416 GPD plasmid. The
Molecular Barcoded Yeast (MoBY) plasmids and empty vector control (p5586)
were kindly provided by the Department of Chemistry & Molecular Biology,
Gothenburg university82. Genomic integration was done by all-in-one plasmids
pECAS9-gRNA-KanMX-XI-3 and pECAS9-gRNA-KanMX-XII-5, which express
high-fidelity version of Cas9 nuclease and guide RNA for XI-3 and XII-5 site
respectively83. The Cas9 cassette and vector backbone were amplified from
pECAS9-gRNA-KanMX-tHFD1 plasmid using primers CAS9-L1/CAS9-R1 and
CAS9-L2/CAS9-R2, respectively. The specific guide RNAs were selected by com-
paring all potential off-targets in the CEN.PK 113-7D genome using the online
CRISPRdirect tool (http://crispr.dbcls.jp/)84. The pECAS9-gRNA-KanMX-XI-3
and pECAS9-gRNA-KanMX-XII-5 plasmids were generated by Gibson Assembly
Master Mix (New England BioLabs). The pYES2 vector expressing GFP-tagged
HTT103QP construct under the GAL1 promoter was described previously85. The
HTT103QP and GFP fragment were amplified and assembled into p416 GPD
vector backbone by Gibson assembly, resulting in p416 GPD-HTT103QP plasmid.
The pUG23 α-syn plasmid expressing a full-length α-synuclein-EGFP sequence
was kindly provided by Prof. Joris Winderickx, KU Leuven, Belgium59. The
standard LiAC/SS carrier DNA/PEG method was used for yeast transformation86.
Control and Aβ42 strains were query strains for SGA screening, which were
constructed through homologous recombination by co-transformation of a repair
fragment and pECA9-gRNA plasmid to Y7092 strain (Supplementary Fig. 1). Two
repair fragments, XI-3up+ (GPDp-Aβ42-CYC1t)+ (TEF1p-natNT2-ADH1t)+
XI-3down and XII-5up+ (GPDp-Aβ42-CYC1t)+ (TEF1p-hphNT1-ADH1t)+
XII-5down, were prepared for two copies of Aβ42 gene integration. The upstream
and downstream homologous arms XI-3up and XI-3down were amplified from
Y7092 genomic DNA with primers XI-3-up-L1/ XI-3-up-R1 and XI-3-down-L/ XI-
3-down-R, respectively. The GPDp-Aβ42-CYC1t, TEF1p-natNT2-ADH1t and
TEF1p-hphNT1-ADH1t cassettes were amplified from p416 GPD-Aβ42, pFA6a-
natNT2 and pFA6a-hphNT1 plasmids, respectively. The upstream and
downstream homologous arms XII-5up and XII-5down were amplified from Y7092
genomic DNA with primers XII-5-up-L/XII-5-up-R and XII-5-down-L2/ XII-5-
down-R, respectively. The repair fragments were assembled by fusing the different
DNA parts with overlapping PCR. For the control strain, the GPDp-CYC1t cassette
was amplified from p416 GPD plasmid. Transformants were selected on YPD plate
supplemented with 100 mg L−1 clonNat (Werner BioAgents) and 300 mg L−1
hygromycin B (Formedium). Control (CEN) and Aβ42 (CEN) strains used for
verification were constructed in CEN.PK 113-11 C background following the same
method. The homologous recombination-based method was used for the
construction of a fmn1 Hsp104-GFP strain. The Hsp104-GFP-Leu fragment along
with 500 bp upstream sequence and 600 bp downstream sequence was amplified
from WT Hsp104-GFP strain (BY4741 background) genomic DNA and
transformed into fmn1 mutant strain to replace endogenous HSP104 sequence. SD-
Leu plates containing 200 mg L−1 G418 (Formedium) were used for selection of
transformants at 22 °C.
Culture conditions. E. coli was grown in LB medium supplemented with 100mg L−1
ampicillin or 50mg L−1 kanamycin at 37 °C. Yeast strains were grown in YPD
medium, Delft medium, SD-Ura medium or SD-Leu medium according to the
auxotrophic and antibiotic phenotypes of the cells (Supplementary Table 6). YPD
medium contained 10 g L−1 yeast extract, 20 g L−1 peptone, and 20 g L−1 glucose.
The recipe of Delft medium was described previously87. 100mg L−1 histidine and/or
100mg L−1 uracil were supplemented when needed. The SD-Ura medium contains
6.7 g L−1 yeast nitrogen base without amino acids (YNB, Formedium), 770mg L−1
complete supplement mixture without uracil (CSM-URA, Formedium) and 20 g L−1
glucose. For SD-Leu medium, 770mg L−1 CSM-URA in SD-Ura medium was
replaced by 690mg L−1 complete supplement mixture without leucine (CSM-LEU,
Formedium). Cells with the MET25 controlled expression cassette for α-synuclein-
EGFP were cultured in Delft medium with 1mM methionine. The α-synuclein-EGFP
expression was induced by depletion of methionine from the medium. Yeast cells
were cultivated at 22 °C for essential temperature sensitive alleles or 30 °C if not
specified. Cell density (OD600nm) was measured using a
GENESYS20 spectrophotometry (Thermo Fisher Scientific).
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SGA analysis. The S.cerevisiae strain Y7092 was used as the SGA starting strain.
Query strains were constructed by chromosomally integrating two copies of GPDp-
Aβ42-CYC1t fragment (sample) with the antibiotic resistance genes (clonNat and
hygromycin B) into Y7092 genome. The yeast single gene knock-out collection
(SGA-V2) and the essential gene temperature sensitive allele collection (ts-V6)
were kindly provided by Prof. Charlie Boone, University of Toronto, Canada.
Thereafter, SGA mating was performed in biological duplicate as previously
described28 to introduce the Aβ42 cassettes into the SGA-V2 and ts-V6 collections.
A control set of the same collections was used as a control for the toxicity assay,
which were constructed by introducing two copies of the GPDp-CYC1t fragment
with the same antibiotic resistance genes. All the pinning steps for collection
handling were performed using a SINGER ROTOR HDA Robot (Singer Instru-
ment). To define genetic interactions, colony sizes of mutants with Aβ42 expres-
sion were quantified from images of final selection plates, and fitness scores relative
to mutants with control were calculated via online SGAtools (http://sgatools.ccbr.
utoronto.ca/)88. A score of >0 represented positive interaction, i.e., increased col-
ony size. While a score of <0 represented negative interaction, i.e., decreased colony
size. Based on these scores, mutants with significantly (p-adj < 0.05) affected Aβ42
toxicity were analyzed for global genetic interactions via spatial analysis of func-
tional enrichment (SAFE) package30. Adjusted P < 0.05 and scores ≤−0.2 or ≥0.2
were set as thresholds to identify significantly affected mutants. Enrichment of GO
terms in gene sets of interests was analyzed using the GOstats package89.
Verification of the putative interactions. To confirm the phenotype observed in
SGA screening, mutants that showed significant differences between Aβ42 and
control were tested manually by random spore analyses and complementation
assays. For Random spore analysis28, spores were first resuspended in 1 ml of sterile
H2O, then 40, 80, 80, and 160 µl of resuspended cells were plated onto agar plates
selecting for the haploid, the single gene mutation, the query-gene expression
(Aβ42 or control), and both single gene mutation and query-gene expression,
respectively. Plates were incubated at 30 °C for 2–3 days. Cell growth under the
four cultural conditions were compared between Aβ42 and control. Mutants with
the Aβ42 expression of which few or no haploids grew on plates were scored as
synthetically lethal. Mutants with the Aβ42 expression of which less haploids grew
on plates comparing to mutants with control were scored as synthetically sick.
Mutants with the Aβ42 expression of which more haploids grew on plates com-
pared to mutants with control were scored as synthetically positive. Com-
plementation assays were performed with a selected group of mutants with Aβ42/
control expression which were complemented with the corresponding MoBY
plasmids or the empty control vector (p5586). Serial dilutions (10-fold) of each
transformant were grown on SD-Ura agar plates at 30 °C for 2–3 days.
Analysis of human brain gene expression data. We analyzed brain expression
datasets from control (N) and AD cases (GN314, GN326, GN327 and GN328)
deposited in the GeneNetwork website (http://www.genenetwork.org) to define the
target gene expression and associate them with AD. The study enlisted approxi-
mately 400 AD cases and 170 controls matched for age, gender and post mortem
interval. Three brain regions (cerebellum, visual cortex, and dorsolateral prefrontal
cortex) from the same individuals were profiled on a custom-made Agilent 44 K
microarray. The individuals were genotyped on two different platforms, the Illu-
mina HumanHap650Y array and a custom Perlegen 300 K array. Differential
expressed genes between control and AD cases were then identified using a Mann-
Whitney test.
NADP(H) and NAD(H) measurements. Enzymatic cycling assays to determine
NADP(H) and NAD(H) levels were performed according to the NADP+/NADPH
Quantification Kit (Sigma) and NAD+/NADH Quantification Kit (Sigma). Cells
were grown in Delft+ 100 mg L−1 histidine+ 100 mg L−1 uracil medium, then 5
OD600nm of cells were collected at later exponential (EX) phase (OD600nm ≈ 2) and
post-diauxic (PD) phases. Collected cells were immediately added to 20 ml of cold
methanol (pre-chilled to −80 °C) to quench cellular metabolism. Cells were cen-
trifuged at −10 °C for 4 min (4000×g), then supernatant was removed. Cell pellets
were freeze-dried for 2 h and stored at −80 °C until measurement. The dried cell
pellet was resuspended in 500 µl of extraction buffer (Sigma) and added to 0.2 g of
prechilled glass beads (425–600 µm diameter, Sigma). Cells were lysed via four
rounds of vortexing for 20 s at speed 6200 rpm on the Precellys Evolution
Homogenizer (Bertin technologies) followed by incubation for 1 min on ice. The
cell lysates were centrifuged at 14000×g for 1 min at 0 °C, and supernatant was used
to measure NADH(H) and NAD(H) amounts following the manufacturer’s
instructions (Sigma).
H2O2 treatment. For growth assays, the Aβ42 strain was grown to mid exponential
phase (OD600nm ≈ 0.5–0.6) in Delft+ 100 mg L−1 histidine+ 100 mg L−1 uracil
medium, the HTT103QP strain was grown to early exponential phase (OD600nm ≈
0.2) in Delft+ 100 mg L−1 histidine medium, and the α-syn strain was grown to
early exponential phase (OD600nm ≈ 0.2) in Delft+ 100 mg L−1 uracil medium,
then 1 ml of cells were distributed on 48-well MTP flowerPlates (m2p-labs). Dif-
ferent concentrations of H2O2 were then added to the cells. Cell growth was
monitored for biological duplicates using a BioLector reader (m2p-labs) and
analyzed with R/growthrates package.
For H2O2 spotting tests, the control strain was grown to stationary phase. 1
OD600nm of cells were pelleted and spotted at a series of 5-fold dilutions onto the
Delft+ 100 mg L−1 histidine+ 100 mg L−1 uracil agar plates containing different
concentrations of H2O2. Plates were then imaged after incubation at 30 °C for
2–3 days.
Quantitative real-Time PCR (qPCR) analysis. qPCR was performed as previously
described90. Aβ42 and control strains were grown in Delft medium supplemented
with 100mg L−1 histidine and 100mg L−1 uracil. Samples were taken from biolo-
gical triplicate cultures during exponential phase and after 1, 2, 3 days of cultivation.
ACT1 was used as a reference gene to normalize RNA levels with primers ACT-L/
ACT-R. FMN1 gene expression was measured with primers FMN1-L2/FMN1-R2.
Fold changes were calculated according to FMN1 gene expression in control strain
and Aβ42 strain, respectively, during exponential phase.
FMN and FAD supplementation. Riboflavin 5′-monophosphate sodium salt
(FMN, Sigma) or riboflavin adenine dinucleotide disodium salt (FAD, Sigma) was
prepared in distilled H2O to 70 mM stock solutions, which was filter-sterilized
using 0.2 µm cellulose acetate filters (VWR). Yeast strains were grown overnight,
diluted to an initial OD600nm of 0.1 in Delft medium or SD-Ura medium. FMN
stock solution was added to the culture to different final concentrations for con-
tinuous treatment. For agar plates, FMN and FAD stock solutions were added to
the final concentration of 5 mM, respectively.
Viability measurement. Viability was measured by propidium iodine (PI, Thermo
Fisher Scientific) staining as described previously23. 0.5 OD600nm of cells were taken
at different culture ages (days) and stained with 0.5 µg ml−1 of PI in the dark at
room temperature for 20 min. The cell pellet was washed twice with PBS and
resuspended in 1 ml of PBS. Fluorescence was analyzed using a Guava flow cyt-
ometer (Merck). In all, 5000 cells were analyzed for each sample. Cells were also
imaged under a fluorescence microscope (Leica DMI4000B) with DIC and RFP
filters. Experiments were performed in biological triplicates.
Inclusion body morphology test. WT Hsp104-GFP and fmn1 Hsp104-GFP
strains were grown to mid exponential phase (OD600nm ≈ 0.5) in SD-Leu medium
with G418 supplement and subjected to a heat shock at 38 °C for 90 min to induce
protein aggregation. Samples were taken after 90 min of heat shock and fixed
immediately in 3.7% formaldehyde. Cells were then imaged with a Carl Zeiss
axiovert 200M microscope (Zeiss). Images were processed with ImageJ (NIH), and
at least 500 cells with aggregates were analyzed and quantified for each sample.
Data is based on the average of six biological replicates.
AZE treatment. L-azetidine-2-carboxylic acid (AZE), an analogue of proline, is
incorporated competitively with proline into proteins during protein synthesis, and
eventually causing conformational changes and protein misfolding91. The control
strain was grown to mid exponential phase (OD600nm ≈ 0.5–0.6) in Delft medium
supplemented with 100 mg L−1 histidine and 100 mg L−1 uracil. AZE (Sigma) was
added to the medium to final concentrations of 5 mM or 10 mM. After 3 h of
cultivation at 30 °C, 0.2 OD600nm of cells were pelleted and resuspended in 1 ml of
sterile H2O. Serial dilutions (10−1, 10−2, 10−3) were used for spot tests on Delft+
100 mg L−1 histidine+ 100 mg L−1 uracil agar plates. Viability was also deter-
mined by colony forming units (CFU) counting. In all, 400 cells were plated on
Delft+ histidine+ uracil agar plates. Plates were incubated at 30 °C for 2–3 days.
Results are from biological triplicates.
Western blot. Aβ42 and control strains were grown to stationary phase in Delft
medium supplemented with 100 mg L−1 histidine and 100 mg L−1 uracil. In all, 5
OD600nm of cells were collected. Whole cell protein extraction and western blotting
were carried out following previous protocols21. Aβ42 levels were identified by a
mouse monoclonal anti-Aβ antibody (6E10, Covance, Catalog Number: SIG-39320,
1:2000 dilution). Anti-GAPDH (Santa Cruz, Catalog Number: sc-365062, 1:2000
dilution) was included as a loading control.
Transcriptome profiling. Samples for RNA-seq analysis were taken from biolo-
gical triplicates of cells grown until late EX phase (OD600nm ≈ 2). In all, 10 OD600nm
of cells were collected in 50 ml falcon tubes containing 25 ml ice and snap-frozen in
liquid nitrogen to prevent mRNA turnover and RNA extraction was performed as
described previously23. RNA-seq was performed by the Novo Nordisk Foundation
Center for Biosustainability of Technical University of Denmark (DTU). The
Illumina TruSeq samples preparation kit v2, with poly-A enrichment, was used for
RNA sequencing. The fragments were clustered on cBot and sequenced on a single
lane on a HiSeq 4000 with paired ends (2 × 150 bp), according to the manu-
facturer’s instructions. The number of read pairs ranged from 12.0 to 16.0 million
for each sample. Raw RNA-seq data was preprocessed by Nfcore-RNA-seq pipeline
(https://github.com/nf-core/rnaseq), developed by the National Genomics Infra-
structure at SciLifeLab, Karolinska Institute. The Report GO terms were performed
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using the Platform for Integrative Analysis of Omics (PIANO) R package92 with
information from the Saccharomyces Genome Database (https://www.
yeastgenome.org/). The functional enrichment of KEGG pathways was analyzed
using the Database for Annotation, Visualization and Integrated Discovery
(DAVID, https://david.ncifcrf.gov/)93,94. The differential gene expression (Log2-
FoldChange) and corresponding significance (p-adj) were calculated by the
Benjamini–Hochberg method and used as input. Heatmaps of significantly chan-
ged GO terms and genes were generated by using pheatmap R package.
Statistics. Significance of differences observed between strains were determined as
mean ± SD using two-tailed student t-test. Three biological replicates were analyzed
unless specified explicitly. Statistical significance was indicated as p < 0.05 unless
specific explicitly.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The RNA-seq raw data can be downloaded from the Genome Expression Omnibus
website (GEO, https://www.ncbi.nlm.nih.gov/geo/) with series number GSE128905. The
data that support the findings of this study are available from the corresponding author
upon reasonable request. The source data underlying Figs. 3c, e, 4a, b, d, 5, 7 and
Supplementary Figs. 11a, 13a, 20, and 22 are provided as a Source Data file.
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